SUBSCRIBE
SUBSCRIBE

BridgeBio LLC

NEWS
Deals
4 Biotech IPOs, and 2 Are Unicorns
Two of this week’s biotech startup initial public offerings, BridgeBio and Adaptive Biotechnologies, have market values exceeding the magic $1 billion mark, and have recently launched initial public offerings (IPOs), but also increased their fundraising goals.
June 27, 2019
 · 
3 min read
 · 
Mark Terry
Deals
Six Biotech Companies with IPOs This Week
This week marked initial public offering news from six biopharma companies. Here’s a look.
June 21, 2019
 · 
3 min read
 · 
Mark Terry
Biotech Bay
BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program
BridgeBio stepped in to take over the drug and also launch a subsidiary, QED Therapeutics, to drive the development of infigratinib.
January 30, 2018
 · 
2 min read
 · 
Alex Keown
Biotech Bay
BioPharm Executive: Money Talk
Venture capital is hopping, attracted to some of the past several years’ successes.
October 14, 2017
 · 
1 min read
 · 
Karl Thiel
3 Biotechs That Could be Taken Out This Quarter
Business
Bay Area Startup BridgeBio Quietly Snags $135 Million From a Bunch of Wall Street Firms
September 13, 2017
 · 
2 min read
3 Biotechs That Could be Taken Out This Quarter
Business
Another Biotech is Born as Bay Area’s BridgeBio Pharma Launches Eidos Therapeutics With $27 Million
April 27, 2017
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Business
BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub
July 21, 2022
 · 
5 min read
Business
BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases
July 21, 2022
 · 
4 min read
Drug Development
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers
June 27, 2022
 · 
7 min read
Drug Development
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
June 22, 2022
 · 
9 min read
Drug Development
BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
June 13, 2022
 · 
12 min read
Drug Development
BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations
June 10, 2022
 · 
5 min read
Drug Development
BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
June 9, 2022
 · 
8 min read
Biotech Bay
BridgeBio Pharma to Participate in June 2022 Investor Events
June 6, 2022
 · 
1 min read
Drug Development
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias
May 26, 2022
 · 
7 min read
Business
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
May 20, 2022
 · 
9 min read
Load More